Metabolic syndrome

Indian Journal of Medical Sciences

Volumn 60, Issue 2, 2006, Pages 72-81

  Gogia, Atul ^a,b   Agarwal, P K ^a  

^a Department of Medicine   (India)

^b Department of Medicine ^*  (India)

Author keywords

Insulin resistance; Metabolic Syndrome; Obesity

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DIET RESTRICTION; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; EXERCISE; GLUCOSE INTOLERANCE; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; OVARY POLYCYSTIC DISEASE; PATIENT EDUCATION; RISK FACTOR; STROKE; UNITED STATES; WEIGHT REDUCTION;

EID: 33645322653     PISSN: 00195359     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5359.19918     Document Type: Article

References (45)

1. Vega GL. Obesity, the metabolic syndrome, and Cardiovascular disease. Am Heart J 2001;142:1108-16.
2. Isomaa B, Almgren P, Tuomi T, Torsen B, Lahti K, Nissen M, et al. Cardiovascular Morbidity and Mortality Associated with the Metabolic Syndrome. Diabetes Care 2001;24:683-9.
3. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
4. Alberti KG, Zimmet PZ. For the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus, provisional report of a WHO Consultation. Diabet Med 1998;15:539-53.
5. Balkau B, Charles MA. Comment on the provisional report from THE who Consultation. European Group for the study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
6. Ford GS, Giles WH, Dietz WH. Prevalence of the Metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
7. Park YW, Zhn S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The Metabolic Syndrome: Prevalence and associated risk factor findings in the US population From the Third National Health and Nutrition Examination Survey, 1993-1994. Arch Intern Med 2003;163:427-36.
8. Cameron AJ, Shaw JE, Zimmet PZ.. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin N Am 2004;33:351-35.
9. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adults - a population study using modified ATP III criteria. Diabetes Res Clin Pract 2003;60:199-204.
10. Gupta A, Gupta R, Sarna M, Rastogi S, Gupta VP, Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diab Res Clin Pract 2003;61:69-76.
11. Deepa R, Shantiram CS, Premlalitha G, Shanti NG, Mohan V. Prevalence of insulin resistance syndrome in a selected south Indian population - the Chennai urban population study-7 [CUPS-7]. Indian J Med Res 2002;115:118-27.
12. Okosun IS, Liao Y, Rotimi CN, Prewitt TE, Cooper RS. Abdominal Obesity and clustering of multiple factors in metabolic syndrome in White, Black and Hispanic Americans. Ann Epidemiol 2000;10:263-70.
13. Wilson PW. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin N Am 2004;33:467-81.
14. Haffner SM, Stern MP, Hazuda HP, Pugh JA, Patterson JK, Malina RM. Upper body and centralized adiposity inn Mexican Americans and non-Hispanic Whites: relationship to body mass index and other behavioral and demographic variables. Int J Obes. 1986;10:493-502.
15. Pekkanen J, Tuomilehto J, Uutela A, Vartiainen E, Nissinen A. Social class, health behaviours and mortality among men and women in eastern Finland. BMJ 1995;311:589-93.
16. Davey SG, Neaton JD, Wentworth D, Stamler J. Mortality differences between black and white men in USA: Contribution of income and other risk factors among men screened for the MRFIT. Lancet 1998;351:934-9.
17. Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation 1993;88:1973-98.
18. Defronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
19. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologica 1991;34:416-27.
20. Manson JE, Willet WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al. Body weight and mortality among women. N Eng J Med 1995;333:677-85.
21. Juahan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997;78:656-60.
22. Thompson SG, Kienast J, Pyke SD, Haverkate F, Van de Loo JC. Hemostatic factors and the risk of Myocardial infarction or sudden death in patients with angina pectoris. N Eng J Med 1995;332:635-41.
23. Ross R. Atherosclerosis: an inflammatory disease. N Eng J Med 1999;340:115-26.
24. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease: insights from the Framingham Study. JAMA 1992;257:1253-6.
25. Munro JM, Cotran RS. Biology of disease: atherogenesis and inflammation. Lab Invest 1988;58:249-61.
26. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, et al. Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly Speedwell Collaborative Heart Disease studies. Circulation 1991;83:836-44.
27. Wilson BW, Kannel WB, Silbershatz I, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-9.
28. Krause RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, et al. AHA dietary guidelines: revision 2000:a statement for health care professionals from the Committee of the American Heart Association. Circulation 2000;102:2284-99.
29. Stein DT, Devaraj S, Balis D, Adams-Huet B, Jialal I. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001;21:2026-31.
30. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelial-dependent vasodilatation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002;87:563-8.
31. Steiner G. Fibrates in the metabolic syndrome and in diabetes. Endocrinol Metab Clin N Am 2004;33:545-6.
32. Eidelman R, Herbert P, Weisman S, Henneken S. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-10.
33. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of anti-platelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 2002;324:71-86.
34. Casson PA, Segal MR, Vokonas PS, Weiss ST. Body fat distribution, blood pressure and hypertension. A prospective cohort study of men in the normative aging study. Ann Epidemiol 1990;1:33-48.
35. Zavaroni I, Mazza S, Dall' AE, Gasparini P, Passeri M, Reavan GM. Prevalence of hyperinsulinaemia in patients with blood pressure. J Intern Med 1992;231:235-40.
36. Appel LJ, Moore FJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Eng J Med 1997;336:1117-24.
37. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary approaches to Stop Hypertension (DASH) diet. N Eng J Med 2001;344:3-10.
38. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events an eight year follow up of 14,719 initially healthy American women. Circulation 2003;107:391-7.
39. Wannamethee SG, Lowe GD, Whincup PH, Whincup PH, Rumley A, Walker M, et al. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002;105:1785-90.
40. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Rimm EB. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res 2003;11:1055-64.
41. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cammon RO 3rd, Criqui M, et al. Markers of Inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Center for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
42. Hooper L, Barlett C, Davey SG, Ebrahim S. Advice to reduce dietary salt for prevetion of cardiovascular disease. Cochrane Database Syst Rev 2004;2:CD003656.
43. Hooper L, Summerbell CD, Higgins JP, Thompson RL, Clements G, Capps N, et al. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev 2004;2:CD002137.
44. US Preventive Services Task Force. Behavioral counselling in primary care to promote a healthy diet: recommendations and rationale. Am J Prev Med 2003;24:93-100.
45. Duncan GE, Perri MG, Theriaque DW, Hutson AD, Eckel RH, Stacpoole PW. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. Diabetes Care 2003;26:557-62.